An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Trial ID # NCT03699449
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Durvalumab, Olaparib
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

Arm B: 14 HRRm Pt-R ovarian cancer, median 4 prior therapies

Therapy Setting

Recurrence

Study Design

Open-Label, Non-randomized

Endpoints

ORR, evaluated per RECIST

Biomarkers

HRRm panel: ATM, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCL, PALB2, PPP2R2A, RAD51 B/C/D, RAD54L

Efficacy

ORR: 35.7% (5PR, n=14) - all responders BRCA1/2 MUT

Conclusion

Olaparib+durvalumab shows promising activity in BRCA MUT patients

Reference

Lee J-Y et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION). J Clin Oncol (2021) 39 (suppl 15; abstr 5520)
https://meetinglibrary.asco.org/record/195558/abstract

Lee J-Y et al. Poster
https://www.clearityfoundation.org/wp-content/uploads/2021/06/AMBITION-study-poster-ASCO-2021-scaled.jpeg

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.